Data / Drug companies / Bracco Diagnostics Inc
Bracco Diagnostics Inc: 36 products in the FDA NDC directory, labeler code 0270
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Bracco Diagnostics Inc (labeler code 0270) lists 36 products in the FDA National Drug Code Directory, covering 11 finished drugs by generic name. By type: 36 prescription drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on January 1, 2026.
The request: Watch Bracco Diagnostics Inc (FDA labeler code 0270): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0270
- Products in commercial distribution
- 36
- Packages
- 69
- Finished drugs by generic name
- 11
- Prescription products
- 36
- Over the counter products
- 0
- Flagged as original packager
- 32 of 32 products that carry the flag
- Started marketing in the last 12 months
- 2
- Earliest marketing start
- February 26, 1958
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 29 | 80.6% |
| Unapproved drugs for a shortage | 7 | 19.4% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 36 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Iomeprol injection | 9 | 2 |
| Iopamidol | 8 | 2 |
| Gadopiclenol | 5 | 2 |
| Sulfur hexafluoride | 4 | 1 |
| Gadoteridol | 2 | 2 |
| Gadobenate dimeglumine | 2 | 1 |
| Diatrizoate meglumine | 2 | 1 |
| Rubidium chloride rb-82 | 1 | 1 |
| Mebrofenin | 1 | 1 |
| Diatrizoate meglumine and diatrizoate sodium | 1 | 4 |
| Sincalide | 1 | 4 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 24 | 66.7% |
| Injection | 5 | 13.9% |
| Injection, powder, lyophilized, for suspension | 2 | 5.6% |
| Kit | 2 | 5.6% |
| Injection, powder, lyophilized, for solution | 2 | 5.6% |
| Liquid | 1 | 2.8% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Radiographic Contrast Agent | 20 |
| Contrast Agent for Ultrasound Imaging | 2 |
| Paramagnetic Contrast Agent | 2 |
| Gadolinium-based Contrast Agent | 2 |
| Radioactive Diagnostic Agent | 1 |
| Cholecystokinin Analog | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Iomervu | 0270-7018 | Injection, solution | New drug applications (NDA) | January 1, 2026 |
| Iomervu | 0270-7017 | Injection, solution | New drug applications (NDA) | January 1, 2026 |
| Vueway | 0270-7035 | Injection | New drug applications (NDA) | September 21, 2022 |
| Vueway | 0270-7030 | Injection | New drug applications (NDA) | September 21, 2022 |
| Vueway | 0270-7025 | Injection | New drug applications (NDA) | September 21, 2022 |
| Vueway | 0270-7020 | Injection | New drug applications (NDA) | September 21, 2022 |
| Vueway | 0270-7015 | Injection | New drug applications (NDA) | September 21, 2022 |
| Iomeron | 0270-9400 | Injection, solution | Unapproved drugs for a shortage | July 1, 2022 |
| Iomeron | 0270-9350 | Injection, solution | Unapproved drugs for a shortage | July 1, 2022 |
| Iomeron | 0270-9300 | Injection, solution | Unapproved drugs for a shortage | July 1, 2022 |
| Iomeron | 0270-7400 | Injection, solution | Unapproved drugs for a shortage | July 1, 2022 |
| Iomeron | 0270-7350 | Injection, solution | Unapproved drugs for a shortage | July 1, 2022 |
| Iomeron | 0270-7300 | Injection, solution | Unapproved drugs for a shortage | July 1, 2022 |
| Iomeron | 0270-7250 | Injection, solution | Unapproved drugs for a shortage | July 1, 2022 |
| Lumason | 0270-7097 | Injection, powder, lyophilized, for suspension | New drug applications (NDA) | April 1, 2021 |
| LumaSon | 0270-7097 | Injection, powder, lyophilized, for suspension | New drug applications (NDA) | April 1, 2021 |
| LumaSon | 0270-7099 | Kit | New drug applications (NDA) | January 15, 2020 |
| LumaSon | 0270-7099 | Kit | New drug applications (NDA) | January 15, 2015 |
| Isovue 370 | 0270-1316 | Injection, solution | New drug applications (NDA) | June 20, 2014 |
| Isovue 300 | 0270-1315 | Injection, solution | New drug applications (NDA) | June 20, 2014 |
| MultiHance | 0270-5264 | Injection, solution | New drug applications (NDA) | November 23, 2004 |
| MultiHance | 0270-5164 | Injection, solution | New drug applications (NDA) | November 23, 2004 |
| ProHance | 0270-1111 | Injection, solution | New drug applications (NDA) | October 9, 2003 |
| ProHance | 0270-1111 | Injection, solution | New drug applications (NDA) | November 16, 1992 |
| CardioGen-82 | 0270-0091 | Injection, solution | New drug applications (NDA) | December 30, 1989 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.